China’s State Administration for Market Regulation (SAMR) has opened an investigation into U.S. chipmaker Qualcomm Incorporated (NASDAQ: QCOM) over alleged violations of the country’s anti-monopoly laws, according to a report by Bloomberg on Friday.
The probe focuses on whether Qualcomm has engaged in business practices that breach China’s competition regulations, potentially impacting its operations in one of its most significant markets. While details of the alleged violations remain undisclosed, such investigations can carry major implications for global tech firms operating in China’s semiconductor industry.
Following the news, Qualcomm shares fell over 3% in pre-market trading, reflecting investor concerns about the potential regulatory and financial consequences of the inquiry.
The move underscores Beijing’s continued scrutiny of major foreign technology companies as part of its broader push to enforce antitrust compliance and maintain fair competition in its domestic markets.


Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026
U.S.–Taiwan Trade Deal Spurs $500 Billion Semiconductor Investment in America
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny
Netflix Plans All-Cash Bid for Warner Bros Discovery Studios Amid Intense Hollywood Takeover Battle
BlueScope Steel Announces A$1 Special Dividend After Asset Sales
Trump Administration Approves Nvidia H200 AI Chip Sales to China Under New Export Rules
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny
Trump Administration Pauses Immigrant Visa Processing for Applicants From 75 Countries
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026
Amazon Reviews Supplier Costs as U.S.–China Tariffs Ease
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO
U.S. Judge Blocks Trump Administration’s $10 Billion Federal Funding Freeze to Democratic States
FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand
Venezuela Releases Political Prisoners Amid Conflicting Counts and Mounting Pressure 



